Glucocorticoids in systemic sclerosis: Weighing up the benefits and risks - a systematic review

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  Iudici, Michele ^a   Valentini, Gabriele ^a   Van der Goes, Marlies C ^b   Bijlsma, Johannes W J ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Glucocorticoids; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ALOPECIA; BONE NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EVIDENCE BASED MEDICINE; FINGER ULCER; FRACTURE; GASTROINTESTINAL SYMPTOM; HAND PAIN; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LEUKOPLAKIA; LOW DRUG DOSE; MONOTHERAPY; MOOD DISORDER; MYOPATHY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RAYNAUD PHENOMENON; REVIEW; RISK BENEFIT ANALYSIS; SCLERODERMA; SCLERODERMA RENAL CRISIS; SERUM SICKNESS; SKIN DISEASE; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; TUBERCULOSIS; VERTIGO; RISK ASSESSMENT;

EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC;

EID: 84883776313     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. LeROY E, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
2. GABRIELLI A, AVVEDIMENTO EV, KRIEG T: Scleroderma. N Engl J Med 2009; 360: 1989-2003.
3. DENTON CP, BLACK CM: Scleroderma--clinical and pathological advances. Best Pract Res Clin Rheumatol 2004; 18: 271-90.
4. CASALE R, BUONOCORE M, MATUCCI-CERINIC M: Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil 1997; 78: 767-73.
5. HUDSON M, THOMBS BD, STEELE R, PANOPALIS P, NEWTON E, BARON M: Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009; 61: 1112-20.
6. STEEN VD, MEDSGER TA, Jr.: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
7. Al-DHAHER FF, POPE JE, OUIMET JM: Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39: 269-77.
8. STEEN VD, MEDSGER TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
9. TYNDALL AJ, BANNERT B, VONK M et al.: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
10. MANNO R, BOIN F: Immunotherapy of systemic sclerosis. Immunotherapy 2010; 2: 863-78.
11. JACOBS JW, BIJLSMA JW: Glucocorticoids in rheumatology: indications and routes of administration. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S81-4.
12. STREHL C, SPIES CM, BUTTGEREIT F: Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S13-8.
13. STEEN VD: Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29: 315-33.
14. GUILLEVIN L, BEREZNE A, SEROR R et al.: Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 2012; 51: 460-7.
15. van der GOES MC, JACOBS JW, BOERS M et al.: Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69: 1913-9.
16. SMITS NA, DURU N, BIJLSMA JW, JACOBS JW: Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S85-92.
17. HUNZELMANN N, MOINZADEH P, GENTH E et al.: High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009; 11: R30.
18. TEH CL, KUAN, WONG JS: Systemic sclerosis in Sarawak: a profile of patients treated in the Sarawak General Hospital. Rheumatol Int 2009; 29: 1243-5.
19. KOWAL-BIELECKA O, LANDEWé R, AVOUAC J et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
20. RANQUE B, AUTHIER FJ, Le-GUERN V et al.: A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009; 68: 1474-7.
21. MEDSGER TA Jr.: Treatment of systemic sclerosis. Curr Opin Rheumatol 1990; 2: 956-9.
22. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
23. LeROY EC, MEDSGER TA Jr.: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
24. BUTTGEREIT F DSJ, BOERS M et al.: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61: 718-22.
25. JADAD AR, MOORE RA, CARROLL D et al.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
26. WELLS GA SB, O'CONNELL D, PETERSON J et al.: The Newcastle-Ottawa Scale (NOS) for assessing the quality if non-randomized studies in meta-analyses. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
27. HOYLES RK, ELLIS RW, WELLSBURY J et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
28. DAVAS EM, PEPPAS C, MARAGOU M, ALVANOU E, HONDROS D, DANTIS PC: Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18: 455-61.
29. BERETTA L, CARONNI M, RAIMONDI M et al.: Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 2007; 26: 168-72.
30. GIACOMELLI R, VALENTINI G, SALSANO F et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.
31. AKESSON A, SCHEJA A, LUNDIN A, WOLLHEIM FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729-35.
32. SWIGRIS JJ, OLSON AL, FISCHER A et al.: Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130: 30-6.
33. DHEDA K, LALLOO UG, CASSIM B, MODY GM: Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23: 306-9.
34. TZELEPIS GE, PLASTIRAS SC, KARADIMITRAKIS SP, VLACHOYIANNOPOULOS PG: Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease. Clin Exp Rheumatol 2007; 25: 734-9.
35. SILVER RM, WARRICK JH, KINSELLA MB, STAUDT LS, BAUMANN MH, STRANGE C: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-44.
36. PAKAS I, IOANNIDIS JP, MALAGARI K, SKOPOULI FN, MOUTSOPOULOS HM, VLACHOYIANNOPOULOS PG: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
37. LIOSSIS SN, BOUNAS A, ANDONOPOULOS AP: Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45: 1005-8.
38. DOMICIANO DS, BONFA E, BORGES CT et al.: A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 2011; 30: 223-9.
39. WANCHU A, SURYANARYANA BS, SHARMA S, SHARMA A, BAMBERY P: High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis 2009; 12: 239-42.
40. TOCHIMOTO A, KAWAGUCHI Y, HARA M et al.: Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year followup. Mod Rheumatol 2011; 21: 296-301.
41. GRIFFITHS B, MILES S, MOSS H, ROBERTSON R, VEALE D, EMERY P: Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371-8.
42. STEEN VD, LANZ JK, Jr., CONTE C, OWENS GR, MEDSGER TA Jr.: Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-6.
43. BEHR J, VOGELMEIER C, BEINERT T et al.: Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154: 400-6.
44. PAI BS, SRINIVAS CR, SABITHA L, SHENOI SD, BALACHANDRAN CN, ACHARYA S: Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Int J Dermatol 1995; 34: 726-8.
45. AIRO P, DANIELI E, ROSSI M et al.: Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 2007; 25: 293-6.
46. AIRO P, DANIELI E, PARRINELLO G et al.: Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22: 573-8.
47. YIANNOPOULOS G, PASTROMAS V, ANTONOPOULOS I et al.: Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007; 27: 357-61.
48. SIMEON-AZNAR CP, FONOLLOSA-PLA V, TOLOSA-VILELLA C et al.: Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2008; 2: 39-45.
49. PEREZ CAMPOS D, ESTEVEZ DEL TORO M, PENA CASANOVAS A, GONZALEZ ROJAS PP, MORALES SANCHEZ L, GUTIERREZ ROJAS AR: Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis?. Reumatol Clin 2012; 8: 58-62.
50. CALGUNERI M, APRAS S, OZBALKAN Z et al.: The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003; 22: 289-94.
51. APRAS S, ERTENLI I, OZBALKAN Z et al.: Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48: 2256-61.
52. De MARCO PJ, WEISMAN MH, SEIBOLD JR et al.: Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-9.
53. VALENTINI G, PAONE C, La MONTAGNA G et al.: Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006; 35: 35-8.
54. VANTHUYNE M, BLOCKMANS D, WESTHOVENS R et al.: A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-92.
55. NADASHKEVICH O, DAVIS P, FRITZLER M, KOVALENKO W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-12.
56. TAKEHARA K: Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 2004; 22 (Suppl. 33): S87-9.
57. SHARADA B, KUMAR A, KAKKER R et al.: Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int 1994; 14: 91-4.
58. OTTEWELL L, WALKER K, GRIFFITHS B: Treatment of skin disease in systemic sclerosis (SSc): Response to a targeted treatment regimen with IV cyclophosphamide (CYC). Rheumatology 2009; 48: i75.
59. SMITH V, Van PRAET JT, VANDOOREN B et al.: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69: 193-7.
60. RANQUE B, AUTHIER FJ, Le-GUERN V et al.: A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009; 68: 1474-7.
61. BURT RK, SHAH SJ, DILL K et al.: Autologous non-myeloablative haemopoietic stemcell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 6; 378: 498-506.
62. MATTESON EL, SHBEEB MI, McCARTHY TG, CALAMIA KT, MERTZ LE, GORONZY JJ: Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 1996; 39: 1132-7.
63. NASH RA, McSWEENEY PA, CROFFORD LJ et al.: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: longterm follow-up of the US multicenter pilot study. Blood 2007;110: 1388-96.
64. OYAMA Y, BARR WG, STATKUTE L et al.: Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007; 40: 549-55.
65. TARKOWSKI A, ANDERSSON-GARE B, AURELL M: Use of anti-thymocyte globulin in the management of refractory systemic autoimmune diseases. Scand J Rheumatol 1993; 22: 261-6.
66. STRATTON RJ, WILSON H, BLACK CM: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40: 84-8.
67. SNOW MH, CANNELLA AC, STEVENS RB, MIKULS TR: Presumptive serum sickness as a complication of rabbit-derived antithymocyte globulin immunosuppression. Arthritis Rheum 2009; 61: 1271-4.
68. SCHMITT WH, HAGEN EC, NEUMANN I, NOWACK R, FLORES-SUAREZ LF, van der WOUDE FJ: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440-8.
69. DeLEA SL, CHAVEZ-CHIANG NR, POOLE JL, NORTON HE, SIBBITT WL, Jr., BANKHURST AD: Sonographically guided hydrodissection and corticosteroid injection for scleroderma hand. Clin Rheumatol 2011; 30: 805-13.
70. AHMAD Q, HASSAN I, MAJID I: Evaluation of dexamethasone pulse therapy in systemic sclerosis. Indian J Dermatol Venereol Leprol 2003; 69: 76-8.
71. SAMEEM F, HASSAN I, AHMAD QM et al.: Dexamethasone pulse therapy in patients of systemic sclerosis: Is it a viable proposition? A study from Kashmir. Indian J Dermatol 2010; 55: 355-8.
72. ANTONIADES L, SFIKAKIS PP, MAVRIKAKIS M: Glucocorticoid effects on myocardial performance in patients with systemic sclerosis. Clin Exp Rheumatol 2001; 19: 431-7.
73. STEEN VD, Jr., MEDSGER TA, Jr.: Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 17; 133: 600-3.
74. TEIXEIRA L, MOUTHON L, MAHR A et al.: Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-6.
75. TRANG G, STEELE R, BARON M, HUDSON M: Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012; 32: 645-53.
76. STEEN VD, MEDSGER TA, Jr.: Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-9.